{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:43:26Z","timestamp":1769114606876,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,7,11]],"date-time":"2006-07-11T00:00:00Z","timestamp":1152576000000},"content-version":"vor","delay-in-days":6280,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[1989,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Commercial concentrates of factor VIII (FVIII) were analyzed in order to 1) determine the effects of viral inactivation on von Willebrand factor (vWF); 2) evaluate the vWF content of the new, immunopurified concentrates; and 3) assess their potential for correcting the long bleeding time of von Willebrand disease (vWD). Included in our study were products that had been treated to inactivate viruses; older, untreated products; and the new, immunopurified concentrates. We measured von Willebrand factor antigen (vWF:Ag), ristocetin cofactor activity (RCoF), and vWF multimeric and subunit composition. A newly developed radioimmunoassay (RIA) was used to quantitate vWF:Ag. The vWF:Ag content varied from 0.083 \u03bcg\/IU FVIII:C for Hemofil M to 32.2 \u03bcg\/IU FVIII:C for Humate\u2010P, whereas pooled normal human plasma (NHP) contained 6.3 \u03bcg\/IU FVIII:C. The RCoF varied from 0.0007 to 2.09 U\/IU FVIII:C, with the immunopurified concentrates having the lowest values and Humate\u2010P the highest. The ratio of RCoF to vWF:Ag ranged from 11 to 96 U\/mg, as compared to a ratio of 160 for NHP. All of the concentrates lacked the largest vWF multimers, and all had abnormal triplet patterns. Modest differences between some untreated concentrates and their treated counterparts were noted. As expected, the immunopurified concentrates had much lower levels of all vWF activities than the conventionally prepared products. Our data suggest that none of the concentrates have as great a capacity as NHP to correct the prolonged bleeding time of von Willebrand disease.<\/jats:p>","DOI":"10.1002\/ajh.2830310108","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T11:46:19Z","timestamp":1172058379000},"page":"41-45","source":"Crossref","is-referenced-by-count":26,"title":["Characterization of von willebrand factor in factor VIII concentrates"],"prefix":"10.1002","volume":"31","author":[{"given":"William A.","family":"Fricke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei\u2010Ying Wong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.236.24.2770"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(76)90751-8"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00825.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1987.tb04892.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830250106"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(78)91322-0"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V55.3.517.517","article-title":"Use of venom coagglutinin and lyophilized platelets in testing for platelet\u2010aggregating von Willebrand factor","volume":"55","author":"Brinkhous KM","year":"1980","journal-title":"Blood"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(78)90148-2"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V55.6.1056.1056"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2007.00901.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.9.4350"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(66)90246-6"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1980.tb02333.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1977.tb01028.x"},{"key":"e_1_2_1_17_2","first-page":"429","article-title":"Factor VIII\u2010related activities in therapeutic concentrates","volume":"97","author":"Barrowcliffe TW","year":"1981","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(87)90374-4"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1988.28188127962.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00359a012"},{"key":"e_1_2_1_21_2","first-page":"96","article-title":"Heterogeneity of human factor VIII. II. Characterization of forms of factor VIII binding to platelets in the presence of ristocetin","volume":"92","author":"Doucet\u2010de Bruine MHM","year":"1978","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2795(81)90228-2"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V57.2.313.313","article-title":"Structural studies on the functional heterogeneity of von Willebrand protein polymers","volume":"57","author":"Martin SE","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood.V53.6.1095.1095","article-title":"Comparison of factor VIII\u2010related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate","volume":"53","author":"Weinstein M","year":"1979","journal-title":"Blood"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1987.tb02981.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112394"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112843"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.18.6550"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.2830310108","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.2830310108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T02:19:10Z","timestamp":1697941150000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.2830310108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,5]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1989,5]]}},"alternative-id":["10.1002\/ajh.2830310108"],"URL":"https:\/\/doi.org\/10.1002\/ajh.2830310108","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,5]]}}}